Introducing PIGMO, a novel PIGmented MOuse model of Parkinson’s disease

Read full text
Authors: Julia Chocarro, Sergio Maraña, María Espelosin, Alberto J. Rico, Goiaz Ariznabarreta, Elena Lorenzo-Ramos, Mario M. Ilarduya, Rubén Hernández-Alcoceba, Miquel Chillón, Miquel Vila, Jeffrey H. Kordower, Anthony H. V. Schapira
+3 more Ana Garcia-Osta, Maria del Mar Cuadrado-Tejedor, Jose L. Lanciego
Cited by: 2
References: 59

Abstract

There is a pressing need for the development, characterization, and standardization of animal models of Parkinson's disease (PD) that properly mimic the cardinal features of this disorder, comprising both the motor phenotype and neuropathological signatures. In the past few years, animal modeling has moved from neurotoxin-based approaches toward viral vectors carrying a given genetic payload of interest. Here, to induce pigmentation of the mouse brain upon systemic delivery, we took advantage of a modified adeno-associated viral vector capsid engineered to bypass the blood-brain barrier and coding for the human tyrosinase gene (AAV9-P31-hTyr). Obtained results revealed an ongoing pigmentation of catecholaminergic centers related to the pathophysiology of PD, such as the substantia nigra pars compacta, ventral tegmental area, and locus coeruleus. Moreover, pigmented dopaminergic neurons exhibited Lewy body-like intracytoplasmic inclusions, a progressive nigrostriatal degeneration, and a time-dependent PD motor phenotype. The bilateral pigmented model of PD generated in this way does not require stereotactic surgery for viral vector delivery, opening up unprecedented possibilities for preclinical testing of therapeutic candidates designed to reduce disease progression rates.

Fields of Study & Subjects

Parkinson's Disease Mechanisms and Treatments Nerve injury and regeneration Virus-based gene therapy research

Publication details

Journal / source
npj Parkinson s Disease
Publisher
Springer Science and Business Media LLC
Volume
12
Issue
1
Publication date
11 February 2026
Language
EN